On November 20, 2018, Generex reported the Company’s wholly owned subsidiary, Antigen Express, Inc. ("Antigen") entered into a Clinical Trial Agreement with NSABP Foundation, Inc. ("NSABP") (Press release, Generex, NOV 26, 2018, View Source [SID1234531634]). Pursuant to the Clinical Trial Agreement, NSABP will conduct a Phase II Study to evaluate efficacy of administering Merck Sharpe & Dhome’s (‘Merck") Keytruda (pembrolizumab) in combination with Antigen’s AE37 cancer vaccine for the treatment of metastatic triple negative breast cancer. While Merck is not a party to the Clinical Trail Agreement, Merck is expected to provide Keytruda for the study pursuant to the Clinical Trial Collaboration and Supply Agreement between Antigen and Merck.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!